Si deseas distinguir tus productos, servicios o ambos de los de otra empresa, es posible que necesites una marca o nombre comercial. Descubre qué son, en qué consiste su procedimiento de registro y qué implica.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Si tienes un nuevo dispositivo, producto o procedimiento que resuelva un problema técnico o tenga una ventaja práctica, existen distintas formas de protegerlo en España y en otros países. Descubre cómo hacerlo.
¿Tu innovación reside en la estética, la ornamentación o la apariencia de tu producto? Protégela mediante un diseño industrial. Descubre qué derechos confiere el registro y cómo realizar la tramitación.
Las indicaciones geográficas protegen el nombre de un producto originario de una zona geográfica, a la cual le debe una determinada calidad, reputación u otra característica. Descubre qué son, en qué consiste su procedimiento de registro y qué beneficios conceden.
Las patentes publicadas en todo el mundo son una valiosa fuente de información científica, técnica y comercial.
La Oficina de Propiedad Intelectual de la Unión Europea cierra la solicitud de ayuda del Fondo para pymes (SME Fund) hasta la siguiente convocatoria en 2026.
Si eres emprendedor/a o una empresa y quieres potenciar y mejorar la rentabilidad de tu negocio protegiendo de forma adecuada los activos intangibles de tu organización, en este espacio encontrarás lo necesario.
136
resultados
Última actualización
28/02/2026 [07:11:00]
Resumen de: WO2026043816A1
In at least one embodiment, a hemoglobin measuring device may include a plurality of sensors, a display configured to present information, and a computing device in communication with the sensors and display and having a processor and a memory storing instructions executable by the processor. The instructions may include instructions to receive, from the sensors, measurements of one or more forms of glycated hemoglobin in a blood samples, determine a total fetal hemoglobin value in the blood sample by performing a peak area summation of all forms of fetal hemoglobin, subtract the total fetal hemoglobin value from 100 to derive a total adult hemoglobin value, determine a glycated fetal hemoglobin value, compare the glycated fetal hemoglobin value to a reference range to obtain a comparison, determine a baseline glucose control value based on the comparison, and output the baseline glucose control value and the comparison to a display for medical evaluation.
Resumen de: US20260053394A1
The present subject matter discloses system (100) and method (700) for detecting and monitoring glucose levels. The system (100) comprising wearable device (200) and wearable device (200) comprising a plurality of transceivers (202) configured for transmitting plurality of power packets to one or more transceivers (202) from plurality of transceivers (202) thereby pushing each of, electrolytes under skin (500) of a user, glucose transmitters and glucose molecules towards surface of the skin (500). Plurality of electrodes (204) configured for collecting ions from body section towards the plurality of electrodes (204). Spectroscopic laser (206) and a spectroscopic detector (208) configured for detecting glucose molecules pushed towards surface of the body section. Processor (210) configured for monitoring the glucose levels according to the detection of the glucose levels.
Resumen de: WO2026043033A1
An electronic device is disclosed. The electronic device may identify that a user has started a meal. The electronic device may identify a blood sugar pattern after the meal is started, the blood sugar pattern being identified on the basis of continuous blood sugar data for the user obtained through a continuous blood sugar measurement sensor. The electronic device may identify foods consumed by the user during the meal on the basis of the blood sugar pattern. On the basis of the foods being identified, the electronic device may display, through a display, a user interface (UI) which includes the names of the foods and induces the user to record a meal event. On the basis of the foods not being identified, the electronic device may display, through the display, another UI for inducing the user to record the meal event without the names of the foods.
Resumen de: US20260053398A1
A blood glucose meter is provided. The blood glucose meter mainly includes a first light source, a second light source, a light sensor, a PPG circuit and a processing unit. The first light source and the second light source respectively emit a first light energy and a second light energy to human skin. The light sensor is used to convert the first light energy and the second light energy reflected off human skin or passing through human skin into a first electrical signal and a second electrical signal. The PPG circuit is configured to generate a first PPG response and a second PPG response according to the first electrical signal and the second electrical signal. A processing unit is configured to execute the following steps: performing feature extraction according to the first PPG response and the second PPG response to obtain a first set of feature values and a second set of feature values; performing an algorithm to obtain a first group of feature ratio values according to the first set of feature values and the second set of feature values; and applying the first group of feature ratio values to a regression model to obtain a blood glucose value.
Resumen de: US20260053395A1
An apparatus that can implement non-invasive blood glucose testing, comprising a parameter acquisition module (101), a feature determination module (102) and a blood glucose determination module (103). The parameter acquisition module (101) is used for acquiring physiological parameters of a subject the blood glucose of which is to be tested and environmental parameters of a current region in which the subject is located, the physiological parameters being acquired by using non-invasive means. The feature determination module (102) is used for obtaining, according to the physiological parameters and the environmental parameters, first input features of the subject, the first input features comprising infrared spectral features and metabolic heat integration features of the subject. The blood glucose determination module (103) is used for inputting the first input features into a blood glucose measuring model, so as to obtain a blood glucose value of the subject by means of the blood glucose measurement model. Using the described apparatus may solve the technical problems in the related technology that invasive blood glucose measuring methods cannot continuously monitor blood glucose and makes patients vulnerable to the risk of infection.
Resumen de: US20260053393A1
Glucose-sensing luminescent dyes, polymers, and sensors are provided. Additionally, systems including the sensors and methods of using these sensors and systems are provided.
Resumen de: EP4699535A2
The present disclosure relates to a continuous blood sugar measuring device, and provides a continuous blood sugar measuring device which is capable of minimizing additional work of a user in order to attach a body attachment unit, by manufacturing the body attachment unit to be assembled inside an applicator so that the body attachment unit can be attached to the body simply by operating the applicator and, particularly: communicating with an external terminal by providing a wireless communication chip in the body attachment unit so that simple and convenient use is possible and maintenance can easily be performed without the additional work of connecting a separate transmitter; initiating operation by a manipulation of the user, after attaching the body attachment unit to the body, so that an operation initiation time can be adjusted to a suitable time according to the need of the user; and initiating operation in a stabilized state to enable a more accurate measurement of blood sugar.
Resumen de: EP4699534A1
An apparatus and a method for non-invasive measurement of blood glucose level are provided, which are capable of driving two or more light sources to emit lights in different wavelength bands toward a part of a body of a user (e.g., a subject), deriving amplitude values from fiducial points in at least one pulse of a respective PPG signal corresponding to each wavelength band, and estimating the blood glucose level of the user using a plurality of amplitude ratios derived from the amplitude values corresponding to different combinations of wavelength bands. The lights emitted by the two or more light sources are in different wavelength bands, indicating that the lights have different characteristics of absorption coefficients for at least glucose and hemoglobin. This helps build the regression model using more data points collected for cross-referencing and calibration compared to using one light source, thereby improving overall accuracy in the estimation of the blood glucose level of the subject.
Resumen de: CA3247818A1
The invention refers to an electronic circuit configured to operate an analyte sensor, such as a glucose sensor, the circuit having at least a first and a second electrical connection configured to be connected to a first and a second electrode of the analyte sensor respectively, wherein the electronic circuit has a voltage source and a common potential conductor section electrically provided on a potential of a pole of the voltage source, wherein with the voltage source an electric potential different to the potential of the common potential conductor section can be provided to the first electrical connection; and wherein the second electrical connection is connected to the common potential conductor section through one or more common potential connection paths and wherein none of the common potential connection paths connects the second electrical connection to the common potential conductor section through fewer than three or more series-connected electronic components.
Resumen de: AU2026200301A1
Abstract Near Infrared Spectroscopy is employed to non-invasively detect blood glucose concentrations, in a multi-sensing detection device. A multi-layered artificial neural network is used to assess these relationships of non-linear interference from human tissue, as well as differences among individuals, and accurately estimate blood glucose levels. Diffuse reflectance spectrum from tlle palm at six different wavelengths analyzed with a neural network, results in a correlation coefficient as high as 0. 9216 when compared to a standard electrochemical glucose analysis test.
Resumen de: US20260047781A1
A porous microneedle array-based interstitial fluid glucose detection device includes a microneedle module, a colorimetric detection module, an electrochemical detection module, and a liquid transport layer. The microneedle module includes a porous microneedle array with a porosity gradient, the porosity gradually increases from the needle tip to the microneedle substrate; the porous microneedle array penetrates human epidermis and extract interstitial fluid, which is then transferred to both the colorimetric detection module and the electrochemical detection module via the liquid transport layer. Within the colorimetric detection module, glucose undergoes a reaction with the color on the colorimetric film, resulting in color development that enables rapid glucose detection; In the electrochemical detection module, glucose undergoes a redox reaction on the working electrode, resulting in the generation of a current signal for the accurate detection of glucose.
Resumen de: US20260047780A1
Disclosed are miniaturized, wearable microneedle biosensor devices, systems, and methods for measuring intradermal concentrations of various metabolites (including but not limited to lactate, pyruvate, and/or glucose) in order to directly assess the viability of living tissue (e.g., human or other mammalian soft tissue). In a variety of implementations, for example, the disclosed microneedle biosensor devices are self-contained in terms of power source, sample acquisition, measurement, and data transmission capabilities, e.g., allowing it to function autonomously once placed. In some implementations, for example, the disclosed microneedle biosensor devices can assess the viability of soft tissue (e.g., skin with or without fat, fascia, or muscle) during and after reconstructive surgery in which soft tissue is repositioned, rotated, or transferred to another site in the body (including but not limited to both microvascular free tissue transfer and regional pedicled flaps).
Resumen de: US20260047785A1
This document discusses, among other things, systems and methods to compensate for the effects of temperature on sensors, such as analyte sensor. An example method may include determining a temperature-compensated glucose concentration level by receiving a temperature signal indicative of a temperature parameter of an external component, receiving a glucose signal indicative of an in vivo glucose concentration level, and determining a compensated glucose concentration level based on the glucose signal, the temperature signal, and a delay parameter.
Resumen de: US20260048196A1
A device is disclosed for delivering medication to a user. The device comprises first and second enclosures that together form a housing of the device, the housing configured to house a reservoir for storing the medication, wherein the first enclosure includes an inner wall of the housing; and a film joined to the inner wall of the first enclosure, wherein the film and the inner wall of the first enclosure are configured to form walls of the reservoir for storing the medication.
Resumen de: WO2026038662A1
This electronic device may receive continuous blood glucose data about a user. Sensing data for identifying the state of the user may be received. The state of the user may include an activity state of the user and a biometric state of the user. The sensing data may include exercise information related to the activity state and biometric information related to the biometric state. Blood glucose patterns may be identified in time intervals in which the activity state and/or the biometric state is identified on the basis of the continuous blood glucose data and the sensing data. A personalized blood glucose pattern may be identified from the blood glucose patterns in the time intervals. The personalized blood glucose pattern may include a pattern in which blood glucose is changed according to the state. A visual object indicating that the personalized blood glucose pattern is identified by the state in a graph representing the continuous blood glucose data may be displayed through a display.
Resumen de: WO2026039036A1
An assembly for securing a glucose monitoring device and related techniques are disclosed. The assembly may include a retainer member configured to fit loosely over the glucose monitoring device without attaching or connecting to it. To that end, the retainer member and a housing of the glucose monitoring device may include respective interfacing features configured to interface with one another. The assembly further may include an adhesive overpatch configured to adhere to the retainer member and the user's skin without adhering to the glucose monitoring device. In accordance with some embodiments, removal of the adhesive overpatch from the user's skin may effectuate simultaneous removal of the retainer member from the glucose monitoring device without compromising adhesion of the glucose monitoring device to the user's skin or disrupting placement of its implanted sensor.
Resumen de: WO2026039326A1
A device is disclosed for delivering medication to a user. The device comprises first and second enclosures that together form a housing of the device, the housing configured to house a reservoir for storing the medication, wherein the first enclosure includes an inner wall of the housing; and a film joined to the inner wall of the first enclosure, wherein the film and the inner wall of the first enclosure are configured to form walls of the reservoir for storing the medication.
Resumen de: AU2024252061A1
Methods and devices include predicting future glucose and engagement levels for a user by receiving the user's glucose levels collected by a continuous glucose monitoring (CGM) device over a time period, receiving engagement data associated with the user, wherein the engagement data are associated with the user's medication intake, diet, physical activity, laboratory results, and education activity, determining a first glycemia risk index (GRI) value, determining, using a machine learning model and responsive to the user's glucose levels and the engagement data collected over the time period, one or more predictions for future glucose levels for the user including a prediction that a future GRI value is greater than or less than the first GRI value, and determining, using the machine learning model and responsive to the user's engagement data collected over the time period, one or more predictions for future engagement levels.
Resumen de: EP4696226A2
In some aspects, a computer-implemented method is disclosed for gathering and processing sensor data to identify a risk of impacting or causing a skin injury. The computer-implemented method can include: receiving, via a computer network, sensor feature data representing output of a user sensor configured to be worn on a limb of a user; generating activity classification model output data using the sensor feature data and an activity classification model, the activity classification model output data representing likelihoods that the sensor feature data corresponds to each of a plurality of different activity classifications; determining an activity classification from the activity classification model output data; and transmitting, via the computer network, display data representing the activity classification to a computing device configured to present the display data.
Resumen de: EP4696344A2
Embodiments of the present disclosure relate to approaches for more efficiently measuring glucose levels using a wearable drug delivery device. In some embodiments, the wearable drug delivery device may include a needle deployment component including a cannula and an optical conduit deployable into a user, the cannula operable to deliver a liquid drug to the user. The wearable drug delivery device may further include a glucose monitor including an optical sensor, the optical sensor operable to measure a light output received via the optical conduit.
Resumen de: US20260041843A1
A processor-implemented method includes obtaining motor rotation data associated with a motor that is configured to rotate steadily to actuate a drive system for driving a plunger of a reservoir in a fluid delivery device; for each rotation of a plurality of rotations of the motor, based on a measured rotation time of the rotation of the motor and a previous maximum rotation time of the motor, determining a current maximum rotation time of the motor and storing the current maximum rotation time in a buffer; determining a coefficient of variation of motor rotation time based on data in the buffer; determining a change of the coefficient of variation of motor rotation time with respect to a baseline coefficient of variation of motor rotation time; and determining whether the plunger is detected based on a comparison of the change and a threshold value.
Resumen de: WO2026034834A1
Disclosed is a sensor module management system comprising a sensor module including a transcutaneous analyte sensor configured to perform a measurement indicating an analyte level and a sensor electronics unit communicatively connected to the transcutaneous analyte sensor, and a mobile device configured to wirelessly communicate with the sensor electronics unit. The sensor module is configured to, when it is confirmed that a command array included in a sub-advertisement event received from the mobile device includes a first command designating a group ID to which the sensor module belongs and a device ID of the sensor module, transmit a first response to the mobile device in response to the first command. The first response includes the analyte level.
Resumen de: US20260041379A1
Method for non-intrusive, needle-free detection of severe hypoglycemia onset through assessment of the cerebral arteriovenous oxygen difference. The method primarily pertains to the treatment of high-risk younger patients with Type 1 Diabetes Mellitus (T1DM) experiencing nocturnal hypoglycemia in order to prevent so called “Death in Bed” syndrome-the sudden death of young diabetic patients without any history of long-term complications.
Resumen de: US20260041375A1
A non-invasive biosignal measurement device based on skin effect removal, includes: a signal measurement instrument measuring a PPG signal of a measurement subject in contact with the skin on one side of a specific body part of the measurement subject; a signal reception unit receiving the PPG signal from the signal measurement instrument; and a ratio value calculation unit removing noise due to a skin effect from the PPG signal, and then calculating ratio values at different wavelengths for measuring a biosignal including blood sugar and glycated hemoglobin of the measurement subject. The signal measurement instrument includes a first sensor module including an optical barrier and a second sensor module for removing the skin effect.
Nº publicación: US20260041337A1 12/02/2026
Solicitante:
YANG DEMAO [US]
Yang Demao
Resumen de: US20260041337A1
Materials and methods of treating a patient with type 2 diabetes mellitus, metabolic syndrome, obesity, infertility, high blood pressure, hyperthyroidism, and hypothyroidism, hyperlipidaemia, osteoporosis, osteoarthritis, hypoadrenalism, polycystic ovary syndrome, or Parkinson's disease comprising administering a therapeutically effective amount of ex vivo cultured activated peripheral blood mononuclear cells (PBMCs) to the patient. The ex vivo cultured activated cells are activated and cultured in a presence of a cytokine and may be autologous or allogeneic relative to the patient.
BOPI
Sede Electrónica
